Insights into biotechnology with Gregg Guerin and Ryan Issakainen

Logo
Presented by

Gregg Guerin, First Trust

About this talk

Investors are now fully aware of the importance that biotechnology companies can have in their portfolios. 2020 presented a fascinating backdrop for the biotech industry with some key updates across regulatory and M&A. The last six months has seen the industry help society mitigate the pandemic by developing testing kits, vaccines and therapeutics. But what are the implications for Biotech with a U.S. election just around the corner? Ryan Issakainen & Gregg Guerin provide some fascinating insight into how this sector has benefitted historically and the short term implications. Some important tailwinds have come into play this year, providing a boost to the sector as a whole, including: U.S. regulators removing red tape surrounding the speed at which new cures & vaccines can hit the market The FDA Commissioner has said: “Permanent change, where needed, will take place” 2017, 2018 and 2019 have been three of the most productive years for drug approvals in the last 20 years M&A activity remains fertile with the cash reserves held by our index names extremely high There are many areas of day-to-day life that are influenced by biotechnology, as the two longest running megatrends in human history combine, we explore the key potential positive implications for the First Trust NYSE ARCA Biotechnology UCITS ETF. The FDA Commissioner has said: “Permanent change, where needed, will take place” 2017, 2018 and 2019 have been three of the most productive years for drug approvals in the last 20 years M&A activity remains fertile with the cash reserves held by our index names extremely high There are many areas of day-to-day life that are influenced by biotechnology, as the two longest running megatrends in human history combine, we explore the key potential positive implications for the First Trust NYSE ARCA Biotechnology UCITS ETF.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (35)
Subscribers (5619)
First Trust is a privately owned U.S. based financial services firm established in 1991. Our mission and approach are simple. We aim to offer investors a better way to invest by providing transparent and innovative solutions - through knowing what we own, investing for the long term, employing discipline and rebalancing our portfolios. These core principles are taken into consideration in all aspects of our business and are the building blocks of our reputation. It is through these principles that First Trust’s specialist investment managers apply a robust and disciplined approach to a range of methodologies. We have a strong track record in providing a variety of rules-based, thematic and actively managed strategies investing across a range of equities, fixed income and alternatives. In delivering our message, our regional sales teams work closely with prospects and clients to distribute First Trust’s range of single-country, regional and global solutions across the world. Today, First Trust is one of the fastest growing ETF providers globally.